Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer.

@article{Oji2004AbsenceOM,
  title={Absence of mutations in the Wilms' tumor gene WT1 in primary breast cancer.},
  author={Yusuke Oji and Yasuo Miyoshi and Eiji Kiyotoh and Satoko Koga and Yoko Nakano and Akiko Ando and Naoki Hosen and Akihiro Tsuboi and Manabu Kawakami and Kazuhiro Ikegame and Yoshihiro Oka and Hiroyasu Ogawa and Shinzaburo Noguchi and Haruo Sugiyama},
  journal={Japanese journal of clinical oncology},
  year={2004},
  volume={34 2},
  pages={
          74-7
        }
}
BACKGROUND It was recently demonstrated that the WT1 gene was overexpressed in primary breast cancer and that the high expression levels of WT1 mRNA significantly correlated with poor prognosis. However, it remained undetermined whether or not the WT1 gene expressed in breast cancer had mutations. METHODS Breast cancer tissues were obtained from 36 patients with breast cancer. WT1 genomic DNA was PCR-amplified and examined for mutations by direct sequencing. RESULTS The sequencing analysis… 
Study of WT1 gene expression in human breast cancer
TLDR
The results suggest that WT1(17AA+) may play oncogenic role in breast carcinoma tissues by upregulation of ER- and HER2, but function of WT1 isoforms should be further explored to address the mechanism in breast cancer.
High Wilms' tumor 1 mRNA expression correlates with basal-like and ERBB2 molecular subtypes and poor prognosis of breast cancer.
TLDR
An oncogenic role of WT1 is confirmed and a possible relation between WT1 and progression of breast cancer is demonstrated, which is shown to be an independent prognostic indicator in multivariate analysis.
Prognostic significance of Wilms Tumor 1 (WT1) protein expression in breast cancer
TLDR
The results indicate that WT1 expression by tumor is more evident in premenopausal state rather than postmenopausal period, and needs to be confirmed with large scale studies onWT1 expression in breast cancer.
Upregulation of Wilms' tumour gene 1 (WT1) in uterine sarcomas.
Overexpression of the Wilms' tumor gene WT1 in primary astrocytic tumors
TLDR
Treatment with WT1 antisense oligomers specifically inhibited growth of glioblastoma cell lines, U87‐MG, A172, and T‐98G, and may indicate that the WT1 gene plays an important role in tumorigenesis of primary astrocytic tumors.
The role of WT1 in breast cancer: clinical implications, biological effects and molecular mechanism
TLDR
The relationship between Wilms' tumor gene 1 and breast cancer is reviewed, including the relationship between expression of WT1 and prognosis of breast cancer patients, and its effectiveness as a target for comprehensive therapy of Breast cancer.
WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy.
  • H. Sugiyama
  • Biology, Medicine
    Japanese journal of clinical oncology
  • 2010
TLDR
Findings suggest that a new era of WT1 immunotherapy is imminent, as WT1-specific cytotoxic T lymphocytes and WT1 antibodies are spontaneously induced in tumor-bearing patients, probably because of high immunogenicity of the WT1 protein.
WT1 Promotes Invasion of NSCLC via Suppression of CDH1
  • Chen Wu, Weiyou Zhu, +4 authors Y. Shu
  • Medicine, Biology
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • 2013
TLDR
WT1 expression was correlated with clinical stage, metastasis, and survival rate in 159 NSCLC patients, and a series of genes were regulated by WT1, and WT1 could suppress CDH1 transcription via direct binding to its promoter and may enhance the invasive ability of H1568 and H1650NSCLC cell lines.
Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population.
TLDR
It is indicated that minor alleles of rs16754, rs5030317 and rs5030320 are associated with reduced risk of breast cancer, suggesting that WT1 SNPs may be a potential biomarker of individualized prediction of susceptibility to breast cancer.
The WT1 Wilms' tumor suppressor gene product interacts with estrogen receptor-alpha and regulates IGF-I receptor gene transcription in breast cancer cells.
TLDR
WT1 suppresses IGF-IR gene transcription in breast cancer cells via a mechanism that involves protein-protein association with ERalpha, and the ability of ERalpha to transactivate the IGF-ir promoter is abrogated.
...
1
2
...

References

SHOWING 1-10 OF 29 REFERENCES
Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers
TLDR
The results suggest that the nonmutated, wild‐type WT1 gene plays an important role in tumorigenesis of de novo lung cancers and may provide the rationale for new therapeutic strategies for lung cancer targeting theWT1 gene and its products.
Wilms' tumor suppressor gene (WT1) is expressed in primary breast tumors despite tumor-specific promoter methylation.
TLDR
expression of WT1 in mammary neoplasia is demonstrated, and that WT1 may not have a tumor suppressor role in breast cancer, suggesting other transcriptional regulatory mechanisms appear to supercede its effects in these tumors.
Overexpression of the Wilms' tumor gene WT1 in primary thyroid cancer
TLDR
An important role of the wild‐type WT1 gene in the tumorigenesis of primary thyroid cancer is indicated, and its expression was restricted to approximately 30–80% of adenoma cells in the tumors examined.
Analysis of the 11p13 Wilms' tumor suppressor gene (WT1) in ovarian tumors.
TLDR
The status of the Wilms' tumor suppressor gene (WT1), residing at chromosome 11 band p13, in a total of 40 cancers of the female reproductive tract, revealed that the WT1 gene is expressed in a large percentage of ovarian tumors analyzed.
WT1 Gene Expression in Human Testicular Germ-Cell Tumors.
TLDR
The results suggest that WT1 may be causal for the progression of testicular germ-cell tumor, and the WT1 gene product acts as a growth promoter of human leukemic cells.
High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients.
  • Y. Miyoshi, A. Ando, +5 authors S. Noguchi
  • Medicine, Biology
    Clinical cancer research : an official journal of the American Association for Cancer Research
  • 2002
TLDR
It is suggested that measurement of WT1 mRNA levels in tumor tissues might be useful as a new prognostic factor in breast cancer patients, independent of the other conventional prognostic factors.
Wilms' tumor gene (WT1) expression in lung cancer, colon cancer and glioblastoma cell lines compared to freshly isolated tumor specimens
TLDR
Testing for WT1 expression is not clinically relevant for colon cancer, lung cancer, or glioblastoma patients, and its expression in cancer cell lines can probably be attributed to optimized in vitro growth conditions.
Downregulation of Wilms' tumor 1 protein inhibits breast cancer proliferation.
Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells.
TLDR
The data presented here support the hypothesis that the WT1 gene plays an essential role in leukemogenesis and performs an oncogenic function in hematopoietic progenitor cells and represent the first demonstration of an important role of theWT1 gene in signal transduction in he matopoiety progenitors cells.
WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia.
TLDR
WT1 is a new prognostic factor and a new marker for the detection of MRD in acute leukemia regardless of the presence or absence of tumor-specific DNA markers.
...
1
2
3
...